Investors
Reselute is developing the first implantable system in the US designed for both mechanical fixation and sustained local antibiotic delivery, addressing the costly and unresolved problem of post-operative infection in fracture care.
Market Opportunity
- 70,000+ tibial fractures annually in the US
- 20%+ infection rates in open fractures
- 3-6x higher cost of care for infected fractures
- No FDA-approved implants combining fixation + local antibiotic delivery
The Reselution™ Tibial Nail
Our lead product is a titanium intramedullary nail with an internal drug reservoir that delivers broad-spectrum antibiotics directly at the surgical site for over six weeks.
It’s designed to provide full weight-bearing support and fits seamlessly into existing surgical workflows. This system is ready off the shelf, fully on-label, and requires less than 10 minutes of intraoperative prep time.
Progress and Milestones
Reselute has received Breakthrough Device Designation from the FDA and completed preclinical studies demonstrating sustained local antibiotic delivery with no systemic toxicity. We’ve conducted over 100 customer discovery interviews, confirming strong clinical demand.
